RecruitingNCT07620067

GnRH for Luteal Support - Mechanism of Action

Gonadotropin-Releasing Hormone Agonist as a Single Luteal Support - What is Its Mechanism of Action?


Sponsor

Heli Alexandroni

Enrollment

150 participants

Start Date

May 18, 2026

Study Type

OBSERVATIONAL

Conditions

Summary

This prospective observational study will include women undergoing IVF treatment with a GnRH antagonist protocol and fresh embryo transfer at the IVF unit of Shaare Zedek Medical Center. Patients will undergo controlled ovarian stimulation followed by ovulation triggering with hCG, GnRH agonist, or dual trigger according to OHSS risk. After oocyte retrieval and fertilization by IVF/ICSI, embryos will be cultured and transferred. Luteal phase support will consist of either intranasal GnRH agonist (Synarel) or vaginal progesterone. Blood and follicular fluid samples will be collected at predefined time points to assess hormonal, inflammatory, and angiogenic markers, including LH, FSH, estradiol, progesterone, IL-6, IL-8, VEGF, PEDF, and relaxin.


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 45 Years

Inclusion Criteria4

  • Women included in the study will be 18-45 years old
  • undergoing IVF treatments due to ovulation disorder, mechanical factor, primary ovarian insufficiency, or male infertility.
  • All women will be at their first to the third cycle of treatment
  • women will undergo a fresh ET.

Exclusion Criteria10

  • repeated implantation failure (more than 3 cycles of good quality ET without implantation)
  • moderate-severe endometriosis
  • hydrosalpinx
  • fibroid uterus
  • BMI more than 35 or less than 19
  • women with hypogonadotropic hypogonadism
  • PGT of embryos
  • use of surgical techniques for sperm retrieval
  • preference of the long GnRH-agonist protocol
  • women with rhinitis or nasal congestion.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGGnRH agonist

spray of 200 mcg Nafarelin (Synarel) twice a day for two weeks

DRUGProgesterone

PV progesterone administered until hCG day and continued for 8-10


Locations(1)

Shaare Zedek Medical Center

Jerusalem, Israel

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07620067


Related Trials